#Sweden #Gothenburg #revenue growth #Zinzino #Faun Pharma

Zinzino AB's Impressive Revenue Surge in February 2025

Zinzino AB, a prominent player in the health and wellness sector, has reported a substantial increase in revenues for February 2025, showcasing an impressive growth trajectory. The company announced that its sales revenue in this month reached SEK 212.7 million, up 56% from SEK 136.4 million compared to the same time last year. This remarkable growth highlights Zinzino's expanding market presence and indicates a strong consumer demand for its products.

Financial Performance Breakdown

A closer look at Zinzino's financial performance reveals that the overall group revenue also experienced a commendable increase of 48%, bringing it to SEK 216.9 million, compared to SEK 146.1 million for the previous year. For the first two months of 2025, Zinzino reported an accumulated revenue of SEK 450.8 million, indicating a growth of 53% from SEK 295 million in 2024.

The revenue growth has been distributed across various key regions:

• - Nordics: Increased by 11% year-on-year to SEK 24.8 million.
• - Central Europe: Showed remarkable growth of 58%, reaching SEK 58.1 million.
• - East Europe: Experienced a slight decline of 4% with revenues of SEK 29.0 million.
• - South West Europe: Recorded a staggering increase of 65%, totaling SEK 37.9 million.
• - The Baltics: Witnessed a modest rise of 11%, amounting to SEK 8.9 million.
• - North America: Surged by an astonishing 181%, generating SEK 32.6 million.
• - Asia-Pacific: Dominated the growth statistics with a phenomenal increase of 485%, hitting SEK 19.9 million.
• - Africa: Showed a growth of 36% with revenues reaching SEK 1.5 million.

Overall, Zinzino's performance in February demonstrates that the company is effectively capitalizing on market opportunities across diverse regions, especially in North America and Asia-Pacific, where growth rates have been exceptionally high. Both regions reflect an increasing consumer recognition of Zinzino’s health-centric product offerings.

Faun Pharma’s Performance

Alongside Zinzino's phenomenal results, it's worth noting that Faun Pharma, another entity within the group, reported a decline in external sales which totaled SEK 4.2 million, down from SEK 9.7 million. This decrease contrasts with Zinzino's robust growth and indicates that while the broader group is thriving, some segments are facing challenges.

Conclusion

As Zinzino AB moves forward in 2025, the overall financial outlook appears promising, especially with the notable successes in various sales markets. The remarkable revenue growth illustrates Zinzino's effective strategy in client engagement and product offerings tailored to meet the evolving needs of consumers. The ongoing expansion across key markets underscores Zinzino's potential for further growth in the coming months. Stakeholders and investors will undoubtedly watch the company closely as it continues to navigate this dynamic landscape and capitalize on these strong growth trends.

For additional insights and the latest updates from Zinzino, the company encourages inquiries through their official website or direct communications with their leadership.

• ---

For more information:
Dag Bergheim Pettersen, CEO Zinzino
Phone: +47 (0) 932 25 700
Website: www.zinzino.com